WS Investor
10 Nov 2026, 15:41
Scholar Rock Falls 5% as ISEMBYLD Launch Begins but Losses Remain Elevated
Scholar Rock (NASDAQ: SRRK) shares fell about 5% on Tuesday despite highlighting early demand for newly launched ISEMBYLD and progress across its international regulatory pipeline.
ISEMBYLD, the first muscle-targeted therapy approved for children and adults with spinal muscular atrophy, received FDA approval on September 11. Scholar Rock shipped product to its specialty network before quarter-end, generating $0.6 million of third-quarter product revenue, with the first patients infused in October.
The company said early U.S. demand has been broad across physicians, treatment centers and patients. In Europe, the apitegromab marketing application was resubmitted and validated in October, with a CHMP opinion expected in the first half of 2027. Japan’s regulator also accepted the drug under priority review.
However, Scholar Rock remains in a heavy investment phase. The company reported a third-quarter net loss of $107.2 million, compared with a $102.2 million loss a year earlier. R&D expense increased to $54.1 million, while SG&A expense was $52.5 million.
Liquidity remains substantial. Scholar Rock ended September with $413.6 million in cash, cash equivalents and marketable securities and recently agreed to sell its Priority Review Voucher for $205 million, providing additional non-dilutive capital.
The 5% decline appears to reflect the very early stage of the ISEMBYLD commercial ramp and continued large operating losses, despite encouraging launch indicators, regulatory progress and a strengthened balance sheet.
Scholar Rock (NASDAQ: SRRK) shares fell about 5% on Tuesday despite highlighting early demand for newly launched ISEMBYLD and progress across its international regulatory pipeline.
ISEMBYLD, the first muscle-targeted therapy approved for children and adults with spinal muscular atrophy, received FDA approval on September 11. Scholar Rock shipped product to its specialty network before quarter-end, generating $0.6 million of third-quarter product revenue, with the first patients infused in October.
The company said early U.S. demand has been broad across physicians, treatment centers and patients. In Europe, the apitegromab marketing application was resubmitted and validated in October, with a CHMP opinion expected in the first half of 2027. Japan’s regulator also accepted the drug under priority review.
However, Scholar Rock remains in a heavy investment phase. The company reported a third-quarter net loss of $107.2 million, compared with a $102.2 million loss a year earlier. R&D expense increased to $54.1 million, while SG&A expense was $52.5 million.
Liquidity remains substantial. Scholar Rock ended September with $413.6 million in cash, cash equivalents and marketable securities and recently agreed to sell its Priority Review Voucher for $205 million, providing additional non-dilutive capital.
The 5% decline appears to reflect the very early stage of the ISEMBYLD commercial ramp and continued large operating losses, despite encouraging launch indicators, regulatory progress and a strengthened balance sheet.
